# US 2014/0154312 A1 · Oral targetted drug delivery system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154312 A1
- Document ID: US20140154312A1
- Status: Published application
- Kind: A1
- Application number: 13/909,159
- Filed: 2013-06-04
- Published: 2014-06-05
- Earliest claimed: 2010-09-17
- Inventors: Monica Gulati; Sima Singh; Sanjiv Duggal; Rahul Satyakam; Mamta Sharma
- Web page: https://patentgrep.com/patent/US20140154312A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/745: Bifidobacteria
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention discloses an “Improved Oral Targetted Drug Delivery System (O-TDDS)” particularly suited for delivery of drugs having activity against the diseases located in the colon e.g. colon cancer, ulcerative colitis, protozoal infections etc. The system comprises two elements or parts viz. microspheres (drug+natural polymers such as guar gum or xanthan gum) and probiotics. Both the elements are packed together in a single, pharmaceutically acceptable oral dosage form such as a capsule. The system offers distinct advantages of drug delivery without undesirable side-effects of diarrhea, nausea or vomiting commonly encountered in case of anti-cancer drugs such as 5-Fluorouracil.

## Claims

### Claim 1

An improved Oral Targetted Drug Delivery System (O-TDDS) wherein the same comprises two elements viz.
i. microspheres which are mixtures of the drug and natural polymers
ii. probiotics in powdered form
packed together in a single, pharmaceutically acceptable oral dosage form such as a capsule.

### Claim 2 (depends on 1)

The drug delivery system of claim 1 wherein the drug is any drug selected from the group comprising known anti-cancer compounds such as 5-Fluorouracil or any other anti-cancer compound.

### Claim 3 (depends on 1)

The drug delivery system of claim 1 wherein the drug is any drug selected from the group comprising colon specific compounds such as Budenoside/Dexamethasone, Dexamethasone, Albendazole, Indomethacin, 5-ASA, Mebendazole, Albendazole/Tinidazole, Celecoxib. Trimetazidine dihydrochloride, Ornidazole, Metoprolol tartrate, Theophylline, Mesalazine, Sennoside, Rofecoxib and Methotrexate.

### Claim 4 (depends on 1)

The drug delivery system of claim 1 wherein the drug is the anti-cancer agent, 5-Fluorouracil.

### Claim 5 (depends on 1)

The drug delivery system of claim 1 wherein the natural polymers are gums such as guar gum or xanthan gum or any other natural polymer.

### Claim 6 (depends on 1)

The drug delivery system of claim 1 wherein the probiotics are any suitable probiotic including but not restricted to Bifidobacterium species such as Bifidobacterium bifidum and Bifidobacterium longum.

### Claim 7

An improved oral targeted drug delivery system as substantially described herein with reference to the detailed description.